HCP
KYMR icon

Hexagon Capital Partners’s Kymera Therapeutics KYMR Stock Holding History

Hexagon Capital Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13
Closed -$356 – 974
2025
Q1 		$356 Buy
13
+10
+333% +$365 ﹤0.01% 1706
2024
Q4 		$121 Buy
+3
New +$135 ﹤0.01% 1804

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Hexagon Capital Partners's KYMR Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 13 shares — an estimated $356 sold.

Hexagon Capital Partners first reported a position in KYMR in Q4 2024 and held it in 2 quarters. The position peaked at $356 in Q1 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 13 Kymera Therapeutics shares in Q2 2025, an estimated $356.
  • Hexagon Capital Partners first reported a position in Kymera Therapeutics in Q4 2024 and held it in 2 quarters.
  • Hexagon Capital Partners's Kymera Therapeutics position peaked at $356 in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.